Company intelligence / Profile preview
NeuroNOS
Boston, MA, USAneuro-nos.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
NeuroNOS has demonstrated compelling preclinical results showing that its small-molecule therapy can regulate nitric oxide levels in the brain, leading to improvements in behavioral and biological markers of autism. The company’s lead candidate, BA-102, has received FDA Orphan Drug Designation for Phelan-McDermid Syndrome. First-in-human clinical trials are planned for 2026.
- Therapeutic areas
- OncologyPsychiatryRare DiseasesNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Hebrew University of Jerusalem/Yissum Technology Transfer CompanyU.S.-based contract manufacturer
Beyond the preview
Go deeper on NeuroNOS.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeuroNOS.